Early Phase III data from Pfizer and BioNTech BNT162b2 is the experimental mRNA-based vaccine candidate from Pfizer and BioNTech’s in Phase III study. Since June, 43,538 participants have been enrolled to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8. On Monday, November 9th, the company announced […]
Moderna published (https://medcitynews.com/2020/09/moderna-publishes-phase-iii-covid-19-vaccine-study-protocol-as-trial-enrolls-more-than-80-of-participants/?rf=1) that the Phase III Covid-19 vaccine study protocol enrolled 25,296 of its planned 30,000 participants which is more than 80% of participants. Of all enrolled subjects, 10,025 have received the full vaccine. This mRNA-1273 Moderna’s vaccine consists of two shots – one delivered on day 1, and a booster shot that participants […]